SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 Certification and Notice of Termination of Registration under Section 12(g) of the Securities Exchange Act of 1934 or Suspension of Duty to File Reports Under Sections 13 and 15(d) of the Securities Exchange Act of 1934. Commission File No. 1-5965 ICN PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) 3300 Hyland Ave. Costa Mesa, CA 92626 (Address, including zip code, and telephone number, including area code, of registrant's principal offices) Common Stock, par value $.01 per share 12 7/8 Sinking Fund Debentures due July 15, 1998 (Titles of each class of securities covered by this Form) NONE Title of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains) Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports. Rule 12g-4(a)(1)(i) [ ] Rule 12h-3(b)(1)(ii) [ ] Rule 12g-4(a)(1)(ii) [ ] Rule 12h-3(b)(2)(i) [ ] Rule 12g-4(a)(2)(i) [ ] Rule 12h-3(b)(2)(ii) [ ] Rule 12g-4(a)(2)(ii) [X] Rule 15d-6 [ ] Rule 12h-3(b)(1)(i) [X] Approximate number of holders of record as of the certification date or notice date: None Pursuant to the requirements of the Securities Exchange Act of 1934, ICN Pharmaceuticals, Inc., the successor to the Registrant, has caused this certification/notice to be signed on its behalf by the undersigned duly authorized persons. /s/ M'Liss Jones Kane DATE: November 10, 1994 By:___________________________ Name: M'Liss Jones Kane Title: Counsel